• Disease
  • Type
  • Type 2
  • Type 2 Diabetes
  • Guillermo E Umpierrez†

    Prominent publications by Guillermo E UMPIERREZ†

    KOL Index score: 17817

    BACKGROUND: Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors. However, few of these patients had HF, and those that did were not well-characterized. Thus, the effects of sodium-glucose co-transporter-2 inhibitors in patients with established HF with reduced ejection fraction, including those with and without type 2 diabetes mellitus, remain unknown.


    Also Ranks for: Reduced Ejection Fraction |  heart failure |  dapagliflozin effects |  patients hf |  functional status
    KOL Index score: 17144

    PURPOSE: To compare the efficacy and safety of subcutaneous insulin lispro with that of a standard low-dose intravenous infusion protocol of regular insulin in patients with uncomplicated diabetic ketoacidosis.

    METHODS: In this prospective, randomized open trial, 20 patients treated with subcutaneous insulin lispro were managed in regular medicine wards (n=10) or an intermediate care unit (n=10), while 20 patients treated with the intravenous protocol were managed in the intensive care ...

    Also Ranks for: Diabetic Ketoacidosis |  subcutaneous insulin |  intravenous regular |  intensive unit |  correction hyperglycemia
    KOL Index score: 16453

    BACKGROUND: The role of incretin-based drugs in the treatment of patients with type 2 diabetes admitted to hospital has not been extensively assessed. In this study, we compared the safety and efficacy of a dipeptidyl peptidase-4 inhibitor (sitagliptin) plus basal insulin with a basal-bolus insulin regimen for the management of patients with type 2 diabetes in general medicine and surgery in hospitals.

    METHODS: We did a multicentre, prospective, open-label, non-inferiority randomised ...

    Also Ranks for: Type 2 Diabetes |  general medicine |  surgery patients |  hospital management |  basal bolus
    KOL Index score: 16214

    OBJECTIVE: To compare the efficacy and safety of two doses of once-weekly dulaglutide, a glucagon-like peptide 1 receptor agonist, to sitagliptin in uncontrolled, metformin-treated patients with type 2 diabetes. The primary objective was to compare (for noninferiority and then superiority) dulaglutide 1.5 mg versus sitagliptin in change from baseline in glycosylated hemoglobin A1c (HbA1c) at 52 weeks.

    RESEARCH DESIGN AND METHODS: This multicenter, adaptive, double-blind, parallel-arm ...

    Also Ranks for: 52 Weeks |  versus sitagliptin |  dulaglutide 075 |  type 2 |  efficacy safety
    KOL Index score: 15857

    OBJECTIVE: Compare the efficacy and safety of monotherapy with dulaglutide, a once-weekly GLP-1 receptor agonist, to metformin-treated patients with type 2 diabetes. The primary objective compared dulaglutide 1.5 mg and metformin on change from baseline glycosylated hemoglobin A1c (HbA1c) at 26 weeks.

    RESEARCH DESIGN AND METHODS: This 52-week double-blind study randomized patients to subcutaneous dulaglutide 1.5 mg, dulaglutide 0.75 mg, or metformin. Patients (N = 807) had HbA1c ≥6.5% ...

    Also Ranks for: Dulaglutide Metformin |  mmol mol |  type 2 |  randomized controlled trial |  efficacy safety
    KOL Index score: 15605

    Importance: Continuous glucose monitoring (CGM) has been shown to be beneficial for adults with type 2 diabetes using intensive insulin therapy, but its use in type 2 diabetes treated with basal insulin without prandial insulin has not been well studied.

    Objective: To determine the effectiveness of CGM in adults with type 2 diabetes treated with basal insulin without prandial insulin in primary care practices.

    Design, Setting, and Participants: This randomized clinical trial was ...

    Also Ranks for: Basal Insulin |  type 2 diabetes |  continuous glucose monitoring |  glycemic control |  8 months
    KOL Index score: 14998

    BACKGROUND: Higher serum urate levels are associated with an increased risk of diabetic kidney disease. Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes and early-to-moderate diabetic kidney disease.

    METHODS: In a double-blind trial, we randomly assigned participants with type 1 diabetes, a serum urate level of at least 4.5 mg per deciliter, an estimated GFR of 40.0 to 99.9 ml per minute per ...

    Also Ranks for: Type 1 Diabetes |  minute 173 |  serum urate |  allopurinol placebo |  diabetic kidney disease
    KOL Index score: 14192

    OBJECTIVE: Renal impairment in type 2 diabetes limits available glucose-lowering treatment options. This trial was conducted to establish the efficacy and safety of liraglutide as an add-on to existing glucose-lowering medications in patients with inadequately controlled type 2 diabetes and moderate renal impairment.

    RESEARCH DESIGN AND METHODS: In this 26-week, double-blind trial, 279 patients with HbA1c 7-10%, BMI 20-45 kg/m(2), and moderate renal impairment (estimated glomerular ...

    Also Ranks for: 2 Diabetes |  liraglutide placebo |  moderate renal |  randomized clinical trial |  efficacy safety
    KOL Index score: 13556

    OBJECTIVE: The optimal treatment of hyperglycemia in general surgical patients with type 2 diabetes mellitus is not known.

    RESEARCH DESIGN AND METHODS: This randomized multicenter trial compared the safety and efficacy of a basal-bolus insulin regimen with glargine once daily and glulisine before meals (n = 104) to sliding scale regular insulin (SSI) four times daily (n = 107) in patients with type 2 diabetes mellitus undergoing general surgery. Outcomes included differences in daily ...

    Also Ranks for: General Surgery |  bolus insulin |  inpatient management |  2 diabetes |  ssi patients
    KOL Index score: 13458

    OBJECTIVE: Effective and easily implemented insulin regimens are needed to facilitate hospital glycemic control in general medical and surgical patients with type 2 diabetes (T2D).

    RESEARCH DESIGN AND METHODS: This multicenter trial randomized 375 patients with T2D treated with diet, oral antidiabetic agents, or low-dose insulin (≤ 0.4 units/kg/day) to receive a basal-bolus regimen with glargine once daily and glulisine before meals, a basal plus regimen with glargine once daily and ...

    Also Ranks for: 2 Diabetes |  surgical patients |  hospital management |  basal regimen |  glargine meals
    KOL Index score: 13301

    Acute and chronic hyperglycemia are proinflammatory states, but the status of proinflammatory cytokines and markers of oxidative stress and cardiovascular risks is not known in hyperglycemic crises of diabetic ketoacidosis (DKA) and nonketotic hyperglycemia (NKH). We studied 20 lean and 28 obese patients with DKA, 10 patients with NKH, and 12 lean and 12 obese nondiabetic control subjects. We measured 1) proinflammatory cytokines (tumor necrosis factor-alpha, interleukin [IL]-6, ...

    Also Ranks for: Proinflammatory Cytokines |  hyperglycemic crises |  lipid peroxidation |  oxidative stress |  cardiovascular risk
    KOL Index score: 13281

    BACKGROUND: The aim of the study was to evaluate the incidence and prognosis of abdominal pain in patients with diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar nonketotic state (HHS). Abdominal pain, sometimes mimicking an acute abdomen, is a frequent manifestation in patients with DKA. The prevalence and clinical significance of gastrointestinal symptoms including abdominal pain in HHS have not been prospectively evaluated.

    MATERIALS AND METHODS: This is a prospectively ...

    Also Ranks for: Abdominal Pain |  hyperglycemic crises |  patients dka |  hyperglycemia dehydration |  diabetic ketoacidosis
    KOL Index score: 13169

    OBJECTIVE: To determine the relative contributions of basal hyperglycemia (BHG) versus postprandial hyperglycemia (PPHG) before and after treatment intensification in patients with glycated hemoglobin A(1c) (A1C) >7.0% while on prior oral therapy.

    RESEARCH DESIGN AND METHODS: Self-measured, plasma-referenced glucose profiles and A1C values were evaluated from participants in six studies comparing systematically titrated insulin glargine with an alternative regimen (adding basal, ...

    Also Ranks for: Treatment Intensification |  postprandial hyperglycemia |  type 2 |  basal insulin |  bhg pphg
    KOL Index score: 12984

    BACKGROUND: Self-monitoring of blood glucose (SMBG) and continuous glucose monitoring (CGM) have been proven effective in improving hemoglobin A1c (HbA1c) and in reducing hypoglycemia in patients with type 1 diabetes mellitus (T1DM). It is not clear, however, if CGM provides further efficacy and safety benefits beyond SMBG in the management of T1DM.

    METHODS: MEDLINE (1966-November 2009), COCHRANE REGISTRY (all years), and EMBASE (1980-November 2009), and article bibliographies were ...

    Also Ranks for: Blood Glucose |  cgm smbg |  diabetes mellitus |  type 1 |  hypoglycemia patients
    KOL Index score: 12796

    OBJECTIVE: This study investigated the safety and efficacy of sitagliptin (Januvia) for the inpatient management of type 2 diabetes (T2D) in general medicine and surgery patients.

    RESEARCH DESIGN AND METHODS: In this pilot, multicenter, open-label, randomized study, patients (n = 90) with a known history of T2D treated with diet, oral antidiabetic agents, or low total daily dose of insulin (≤0.4 units/kg/day) were randomized to receive sitagliptin alone or in combination with glargine ...

    Also Ranks for: Surgery Patients |  general medicine |  inpatient management |  type 2 |  treatment sitagliptin


    Guillermo E UMPIERREZ†: Influence Statistics

    Sample of concepts for which Guillermo E UMPIERREZ† is among the top experts in the world.
    Concept World rank
    gv hospital complications #1
    hyperglycemia clinical #1
    reduced costs day #1
    ketosis resistant #1
    dings process #1
    hospitalization diabetes education #1
    award3 #1
    bhg total hyperglycemia #1
    dental loss #1
    inpatient hypoglycemia #1
    nearnormoglycemia remission patients #1
    diabetes complications usa #1
    hyperglycemia relapse oad #1
    hba1c attainment #1
    regular health paraguay #1
    medical literature topics #1
    hbgi prandial hbgi #1
    634552mg #1
    hospitalization higher rates #1
    diabetes poor compliance #1
    hyperglycemic crisis akt1 #1
    obesity hospital complications #1
    noncritically patients hyperglycemia #1
    33 26 weeks #1
    day nph regular #1
    combined hyperglycemia ffa #1
    insulin incretin therapy #1
    liraglutide hospital discharge #1
    impaired expression akt2 #1
    complications racial #1
    hypoglycemia incidence factors #1
    aka dka #1
    ffa combined infusion #1
    hyperglycemia enteral #1
    resolution hyperglycemia #1
    insulin ssi #1
    t2d general medicine #1
    cardiac surgery purpose #1
    reviewoutpatient #1
    treatment basalbolus #1
    obesity progression mass #1
    management diabetic patient #1
    hhs mortality #1
    hospitalists inpatient notes #1
    complications hospitalization costs #1
    ketoacidosis complications #1
    insulin glargine longterm #1
    lixisenatide fpg #1
    article blood glucose #1
    higher gv #1

    Key People For Type 2 Diabetes

    Top KOLs in the world
    David Richard Matthews
    type 2 diabetes sri lanka growth hormone
    Frank B Hu
    type 2 diabetes cardiovascular disease physical activity
    Rury R Holman
    type 2 diabetes cardiovascular disease impaired glucose tolerance
    David Matthew Nathan
    type 2 diabetes insulin resistance cardiovascular disease
    John B Buse
    type 2 diabetes insulin degludec cardiovascular outcomes
    Tuomilehto Tuomilehto
    type 2 diabetes blood pressure north karelia

    Guillermo E UMPIERREZ†:Expert Impact

    Concepts for whichGuillermo E UMPIERREZ†has direct influence:Type 2 diabetes,  Diabetic ketoacidosis,  2 diabetes,  Type 2,  Hospitalized patients,  Basal insulin,  Hyperglycemic crises,  Diabetes mellitus.

    Guillermo E UMPIERREZ†:KOL impact

    Concepts related to the work of other authors for whichfor which Guillermo E UMPIERREZ† has influence:Type 2 diabetes,  Diabetic ketoacidosis,  Glycemic control,  Blood glucose,  Heart failure,  Hospitalized patients,  Insulin therapy.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Department of Medicine, Division of Endocrinology at Emory University, Atlanta, GA, USA. | American Diabetes Association, 1400 16th St NW #410, Washington, DC 20036. Electronic address: geumpie@emory.edu. | Emory University, Atlanta, GA, USA. | Profe